1. Home
  2. KRRO vs CUE Comparison

KRRO vs CUE Comparison

Compare KRRO & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

SELL

Current Price

$12.67

Market Cap

196.4M

Sector

Health Care

ML Signal

SELL

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

SELL

Current Price

$14.23

Market Cap

177.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
KRRO
CUE
Founded
2014
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
196.4M
177.0M
IPO Year
2019
2017

Fundamental Metrics

Financial Performance
Metric
KRRO
CUE
Price
$12.67
$14.23
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
3
Target Price
$21.50
★ $88.00
AVG Volume (30 Days)
★ 212.2K
126.6K
Earning Date
11-05-2026
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 61.11
EPS
★ N/A
N/A
Revenue
$6,392,000.00
★ $27,466,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
181.46
★ 195.75
52 Week Low
$5.20
$0.17
52 Week High
$17.35
$45.50

Technical Indicators

Market Signals
Indicator
KRRO
CUE
Relative Strength Index (RSI) 48.28 33.14
Support Level $11.81 $0.22
Resistance Level $14.47 $33.95
Average True Range (ATR) 1.45 2.25
MACD -0.22 -0.18
Stochastic Oscillator 24.60 7.45

Price Performance

Historical Comparison
KRRO
CUE

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Share on Social Networks: